The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

J. S. Kennedy, A. Zagar, F. Bymaster, G. Nomikos, P. T. Trzepacz, J. A. Gilmore, M. D. Rotelli, A. Breier, G. Tollefson

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

Objective: The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. Methods: Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline. Results: There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups. Conclusion: Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.

Original languageEnglish (US)
Pages (from-to)S24-S32
JournalInternational Journal of Geriatric Psychiatry
Volume16
Issue numberSUPPL. 1
DOIs
StatePublished - 2001

Keywords

  • Alzheimer's disease
  • Olanzapine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Kennedy, J. S., Zagar, A., Bymaster, F., Nomikos, G., Trzepacz, P. T., Gilmore, J. A., Rotelli, M. D., Breier, A., & Tollefson, G. (2001). The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. International Journal of Geriatric Psychiatry, 16(SUPPL. 1), S24-S32. https://doi.org/10.1002/1099-1166(200112)16:1+<::aid-gps570>3.0.co;2-8